Drug-therapy combo cuts breast cancer recurrence risk by 25%, Eli Lilly announces

Drug-therapy combo cuts breast cancer recurrence risk by 25%, Eli Lilly announces

Eli Lilly and Company on Sunday announced positive results on the fight against breast cancer.